Recommended

Novo Nordisk invests €500m in oral GLP-1 manufacturing
New webinar | Optimising efficiency and yield through bioprocessing automation | 13 May at 3PM | REGISTER NOW!
Moderna’s mCombriax vaccine potential EU approval
WEBINAR | Harnessing AI for more efficient clinical trials | REGISTER TODAY
Ayvakit potential long-term treatment in indolent systemic mastocytosis
UCB invests $1.1bn in immunology with Antengene collaboration
Biogen/Stoke’s zorevunersen shines in clinical readout
Sanofi and Sino Biopharma collaborate in $1.5bn licensing deal
LAST CHANCE TO REGISTER | Harnessing digital PCR for rapid sterility testing
Practical steps for innovating pharmaceutical manufacturing
news

Treating malaria using artemisinin-based combination therapy (ACT)

20
SHARES

The artemisinin-based combination therapy (ACT), pyronaridine-artesunate, has been shown to be as effective in treating malaria as other drugs…

ACT

A study has given insight on the efficacy of using artemisinin-based combination therapy (ACT), pyronaridine-artesunate, for the treatment of malaria in areas of the world where resistance to other ACTs is now becoming a problem.

 

LAST CHANCE TO REGISTER!


Rapid sterility testing is no longer optional for advanced therapies – it’s becoming operationally essential. Join this webinar to explore rapid sterility testing methods that ensure fast, reliable product release, addressing critical challenges in timely delivery and safety.

Harnessing digital PCR for rapid sterility testing

18 March 2026 | 3PM

What you’ll discover:

  • Rapid sterility testing methods that address the challenge of lengthy testing times, improving efficiency and ensuring timely product release
  • Insights into how digital PCR technology enhances testing accuracy and sensitivity, detecting contaminants quickly and reliably
  • Real-world case studies on rapid testing implementations in the field of cell and gene therapy

The session will discuss future trends in sterility testing and showcase successful rapid sterility testing in cell and gene therapy products, demonstrating practical applications and benefits.

Register now to join the discussion

The researchers found this treatment to be as effective as the currently used treatment, and in some cases was better. Researchers at the Liverpool School of Tropical Medicine, looked at results from ten clinical trials that made a comparison between pyronaridine-artesunate and other currently used treatments for people affected by Plasmodium falciparum malaria. 

The World Health Organization (WHO) currently recommends that ACTs are used to treat uncomplicated P. falciparum malaria. However, due to their ongoing artemisinin resistance, global initiatives have been launched to develop new and partner drugs to protect the efficacy of the original treatment.

The independant authors, Joseph Pryce and Dr Paul Hine assessed the efficacy of pyronaridine-artesunate for the treatment of malaria.

The corresponding author of the study, Dr Hine, said: “The need to find novel ACTs is important so that we can protect the efficacy of the artemisinin derivatives within them. The evidence that we found clearly showed at pyronaridine-artesunate performs as well, if not better than some of the currently marketed ACTs.”

Of the ten studies investigated, five of them specifically looked at the safety of the drug, with two of the trials exclusively recruiting children under the age of 12.

Pryce, one of the authors, said: “We found that pyronaridine-artesunate did increase the risk of having blood tests that showed mild liver injury, but there was no evidence that this caused severe or irreversible damage.

“The findings of this review’s efficacy analysis support the recommendation for using pyronaridine-artesunate in areas of multiple drug resistance, providing effective malaria treatment where other treatments may be failing.”

The full study can be found here.

 
Share via
Share via